Annals of Hematology

, Volume 91, Issue 11, pp 1703–1712 | Cite as

FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India

  • Kanjaksha Ghosh
  • Suchitra Swaminathan
  • Manisha Madkaikar
  • Maya Gupta
  • Lily Kerketta
  • Baburao Vundinti
Original Article


Acute myeloid leukemia (AML) is an aggressive hematological disorder characterized by the loss of ability of the hematopoietic progenitor cells to differentiate and proliferate normally leading to an accumulation of immature myeloid cells in the bone marrow. Several novel molecular genetic aberrations in FLT3 and NPM1 have been shown to have a prognostic impact in AML, particularly in those having normal karyotype. Though there is substantial amount of data on these mutations from western literature, there is surprisingly little data from Indian subcontinent on the frequency of this mutation in AML patients from India. The present study screens a large cohort of non-acute promyelocytic leukemia (APL) AML patients (207 patients) for the presence of FLT3 and NPM1 mutations and further correlates with cytogenetics, immunophenotypic characteristics and with follow-up data wherever available. During the course of study, 56 APL patients were also studied. Briefly, both FLT3 (internal tandem duplication (ITD) in 19.4 % and tyrosine kinase domain (TKD) in 9 %) and NPM1 mutations were detected in 28.4 % of the total non-APL AML patients screened showing distinct correlations with hematologic, immunophenotypic, cytogenetics characteristics and follow-up. With regards to adult APL patients, 22.2 and 32.6 % of the patients showed FLT3 and NPM1 mutation, respectively. In the pediatrics age group (<15 years), 23 and16 % of patients with APL showed FLT3 and NPM1 mutation, respectively, while in non-APL patient is this age group, 23 % of patients showed both FLT3 and NPM1 mutation. NPM1 mutation was distinctly uncommon in younger age group of patients. In contrast to report elsewhere, most of our FLT3 mutation was in exon 11 rather than in exon 12. FLT3mutation due to ITD or TKD mutation was detected in 2:1 ratio in our patients and a new TKD mutation was also detected S840G in an M5 patient who did not go into remission and had a short survival of 3 months from diagnosis. Generally, patients with NPM1 mutation had a very high white cell count but they went into remission more often than those with wild (Wt)-type allele (written as NPM1− and FLT3−, respectively) and FLT3 mutation. These patients also tended to have significantly lower expression of CD34 antigen on flowcytometry. Distinct prognostic subclasses of adult AML patients were identified based on the presence of NPM1 and FLT3 mutations.


AML FLT3 mutations NPM1 mutations 



The authors want to thank Dr. Srimati Shetty, Dr. Sonal Vora, Dr. Mansi Vijapurkar Dr. Bipin Kulkarni, Ms. Seema Korgaonkar, and Ms. Leena Sonawane (NIIH-ICMR) for invaluable contributions to the progression of these studies. Ms. Swati Garg provided considerable help during revision of this paper.

Conflicts of interest

The authors declare no competing financial interests.


  1. 1.
    Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W (2004) Adult acute myeloid leukaemia. Critical Rev Oncolo/Hematol 50:197–222CrossRefGoogle Scholar
  2. 2.
    Mrozek K, Heinonen K, Bloomfield CD (2001) Clinical importance of cytogenetics in acute myeloid leukemia. Best Pract Res Clin Haematol 14:19–47PubMedCrossRefGoogle Scholar
  3. 3.
    Schnittger S, Schoch C, Dugas M et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59–66PubMedCrossRefGoogle Scholar
  4. 4.
    Verhaak RG, Goudswaard CS, van Putten W et al (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747–3754PubMedCrossRefGoogle Scholar
  5. 5.
    Nakao M, Yokota S, Iwai T et al (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911–1918PubMedGoogle Scholar
  6. 6.
    Dibb NJ, Dilworth SM, Mol CD (2004) Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4:718–727PubMedCrossRefGoogle Scholar
  7. 7.
    Jiang J, Paez JG, Lee JC et al (2004) Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 104:1855–1858PubMedCrossRefGoogle Scholar
  8. 8.
    Kindler T, Breitenbuecher F, Kasper S et al (2005) Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 105:335–340PubMedCrossRefGoogle Scholar
  9. 9.
    Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S (2002) A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 100:3423–3425PubMedCrossRefGoogle Scholar
  10. 10.
    Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12:1333–1337PubMedCrossRefGoogle Scholar
  11. 11.
    Dohner K, Schlenk RF, Habdank M et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740–3746PubMedCrossRefGoogle Scholar
  12. 12.
    Schnittger S, Schoch C, Kern W et al (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with normal karyotype. Blood 106:3733–3739PubMedCrossRefGoogle Scholar
  13. 13.
    Thiede C, Koch S, Creutzig E et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011–4020PubMedCrossRefGoogle Scholar
  14. 14.
    Falini B, Mecucci C, Tiacci E et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype. N Engl J Med 352:254–266PubMedCrossRefGoogle Scholar
  15. 15.
    Suzuki T, Kiyoi H, Ozeki K et al (2005) Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854–2861PubMedCrossRefGoogle Scholar
  16. 16.
    Falini B, Nicoletti I, Bolli N et al (2007) Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Hematologica 92:519–532CrossRefGoogle Scholar
  17. 17.
    Boonthimat C, Thongnoppakhun W, Auewarakul CU (2008) Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica 93:1565–1569PubMedCrossRefGoogle Scholar
  18. 18.
    Arber DA (2001) Realistic pathologic classification of acute leukaemias. Am J Clin Pathol 115:552–560PubMedCrossRefGoogle Scholar
  19. 19.
    Rothe BHG, Schmitz G (1996) Consensus document on leukemia immunophenotyping. European working group on clinical cell analysis (EWGCCA). Leukemia 10:877–895PubMedGoogle Scholar
  20. 20.
    Mitelman F (1995) ISCN 1995: an international system for human cytogenetic nomenclature. Karger, BaselGoogle Scholar
  21. 21.
    Crescenzi B, Fizzotti M, Piattoni S et al (2000) Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants. Cancer Genet Cytogenet 120:25–29PubMedCrossRefGoogle Scholar
  22. 22.
    Sambrook J, Fritschi EF, Maniatis T (1989) Molecular cloning: a laboratory manual. Isolation of high-molecular-weight DNA from mammalian cells using proteinase K and phenol, 2nd edn. Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar
  23. 23.
    Mohammad HS, Abida A, Khalid T, John ALY (2003) Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Hematol J 4:41–46CrossRefGoogle Scholar
  24. 24.
    Schnittger K, SchochC DM et al (2002) Analysis of FLT3 length mutation in 1003 patients with acute myeloid leukaemia: correlation to cytogenetics, FAB subtype and prognosis in the AMLCG study and usefulness as a marker for detection of minimal residual disease. Blood 100:59–66PubMedCrossRefGoogle Scholar
  25. 25.
    Baldus CD, Thiede C, Soucek S et al (2006) BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukaemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 24:790–797PubMedCrossRefGoogle Scholar
  26. 26.
    Brunet S, Labopin M, Esteve J et al (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated haematopoietic transplantation for adult acute myeloid leukaemia in first remission: a retrospective analysis. J Clin Oncol 30:735–741PubMedCrossRefGoogle Scholar
  27. 27.
    Sazawal S, Kumar B, Hasan SK et al (2009) Haematological and molecular profile of acute myelogenous leukaemia in India. Indian J Med Res 129(3):256–261PubMedGoogle Scholar
  28. 28.
    Hasan SK, Sazawal S, Dutta P et al (2007) Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications. Hematology 12:99–101PubMedCrossRefGoogle Scholar
  29. 29.
    Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M (2007) Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica 92:994–995PubMedCrossRefGoogle Scholar
  30. 30.
    Sheikhha MH, Awan A, Tobal K, Liu Yin JA (2003) Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Hematol J 4:41–46PubMedCrossRefGoogle Scholar
  31. 31.
    Stirewalt DL, Kopecky KJ, Meshinchi S et al (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589–3595PubMedCrossRefGoogle Scholar
  32. 32.
    Shih LY, Huang CF, Wu JH et al (2004) Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res 10:1326–1332PubMedCrossRefGoogle Scholar
  33. 33.
    Abu-Duhier FM (2000) GoodeveAC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 111:190–195PubMedCrossRefGoogle Scholar
  34. 34.
    Kottaridis PD, Gale RE, Frew ME et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–1759PubMedCrossRefGoogle Scholar
  35. 35.
    Frohling S, Schlenk RF, Breitruck J et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100:4372–4380PubMedCrossRefGoogle Scholar
  36. 36.
    Boissel N, Cayuela JM, Preudhomme C et al (2002) Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 16:1699–1704PubMedCrossRefGoogle Scholar
  37. 37.
    Gale RE, Hills R, Pizzey AR et al (2005) The relationship between FLT3 mutation status, biological characteristics and response to targeted therapy in acute promyelocytic leukemia. Blood 106:3768–3776PubMedCrossRefGoogle Scholar
  38. 38.
    Yan L, Chen S, Liang J et al (2007) Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia. Int J Hematol 86:143–146PubMedCrossRefGoogle Scholar
  39. 39.
    Ahmad F, Mandava S, Das BR (2009) Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol 27:90–97PubMedCrossRefGoogle Scholar
  40. 40.
    Chou WC, Tang JL, Lin LI et al (2006) Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 66:3310–3316PubMedCrossRefGoogle Scholar
  41. 41.
    Yamamoto Y, Kiyoi H, Nakano Y et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434–2439PubMedCrossRefGoogle Scholar
  42. 42.
    Thiede C, Steudel C, Mohr B et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326–4335PubMedCrossRefGoogle Scholar
  43. 43.
    Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4):1262–1270PubMedCrossRefGoogle Scholar
  44. 44.
    Frohling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 23:6285–6295PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Kanjaksha Ghosh
    • 1
  • Suchitra Swaminathan
    • 1
  • Manisha Madkaikar
    • 1
  • Maya Gupta
    • 1
  • Lily Kerketta
    • 1
  • Baburao Vundinti
    • 1
  1. 1.Indian Council of Medical Research (ICMR)National Institute of ImmunohaematologyMumbaiIndia

Personalised recommendations